Available Technology

Therapeutic for Prostate Cancer, Diabetes, and Contraceptives

The National Cancer Institute's Urologic Oncology Branch is seeking statements of capability or interest from parties interested in licensing a therapeutic against prostate cancer.

Benefits 
The compounds do not compete with androgens and specifically inhibit FKBP52-enhanced AR function -Potential for synergistic use with conventional anti-androgens for treatment of androgen resistant prostate cancer
Inventors: 

Len Neckers

Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin